Page last updated: 2024-12-07

1-hydroxybenzotriazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Hydroxybenzotriazole (HOBt) is a heterocyclic organic compound with the formula C6H4N2OH. It is a white solid that is widely used in organic synthesis as a reagent for the activation of carboxylic acids for amide bond formation. HOBt acts as a catalyst and is commonly used in peptide synthesis, where it helps to prevent racemization of the amino acids. HOBt is also used in the synthesis of other amides, such as those found in pharmaceuticals and agrochemicals. The importance of HOBt lies in its ability to accelerate the formation of amides while minimizing side reactions. Its use in peptide synthesis allows for the efficient production of complex peptides with high purity. HOBt is a versatile reagent in organic synthesis due to its ability to promote the formation of various functional groups, including amides, esters, and ureas. The mechanism of action involves the formation of an active ester intermediate, which readily reacts with amines to form the desired amide product. The study of HOBt and its derivatives is ongoing, focusing on developing new and improved methods for amide bond formation. Current research aims to explore the use of HOBt analogs with enhanced reactivity and selectivity, potentially leading to more efficient and environmentally friendly synthetic processes.'

1-hydroxybenzotriazole: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID75771
CHEMBL ID1389920
CHEBI ID176967
SCHEMBL ID184
SCHEMBL ID3672275
SCHEMBL ID2845655
SCHEMBL ID3295216
MeSH IDM0058470

Synonyms (108)

Synonym
CHEBI:176967
a2t929dmg4 ,
unii-a2t929dmg4
1h-benzotriazole, 1-hydroxy-
benzazimidol
MLS001006716
smr000349651
brn 0004515
1-hydroxy-1h-benzotriazole hydrate
benzazimidol hydrate
einecs 219-989-7
1h-benzotriazole, 1-hydroxy-, hydrate
1-hydroxybenzotriazole
ccris 2605
2592-95-2
1-hydroxy-1-h-benzotriazole
AC-2558
1h-benzotriazol-1-ol
FT-0652486
HMS1724G04
AKOS000120715
NCGC00246157-01
HMS2742F11
1h-1,2,3-benzotriazol-1-ol
1-hydroxy-1h-benzotriazol
n-hydroxybenzotriazol
1-hydroxy benzotriazole
1-hydroxybenzotriazol
1-hydroxy-1h-benzotriazole
1-hydroxy-benzotriazole
cas-2592-95-2
dtxcid1024627
tox21_302480
NCGC00256701-01
dtxsid3044627 ,
A818093
1h-benzo[d][1,2,3]triazol-1-ol
1,2,3-benzotriazol-1-ol
H0468
n-hydroxybenzotriazole
1-hydroxyl-1h-benzotriazole
CHEMBL1389920
BP-12840
FT-0601979
AB-131/40192094
AM84845
1-hydroxy-1h-benzotriazole [mi]
1-benzotriazolol
CS-B0704
SCHEMBL184
SCHEMBL3672275
SCHEMBL2845655
J-504791
hobo
n-hydroxybezotriazole
1-hydroxy-1h-1,2,3-benzotriazole
n-hydroxy benzotriazole
l-hydroxybenzotriazole
1-hydroxibenzotriazol
1h-benzotriazole-1-ol
3-hydroxybenzotriazole
1-hydroxy-(1h)-benzotriazole
n-hydroxy-benzotriazole
1-hydroxybenztriazole
1-hydroxy-bezotriazole
1-hydroxy-benzo-triazole
n-hydoxybenzotriazole
1-hydroxy-benztriazole
1-hydroxybenzotri-azole
1-hydroxy-1,2,3-benzotriazole
1-hydroxy-1h-benztriazole
benztriazol-1-ol
1- hydroxybenzotriazole
n-hydroxybenztriazole
1-hydroxylbenzotriazole
1-hydroxybenzo-triazole
benzotriazol-1-ol
1-h-1,2,3-benzotriazol-1-ol
1-hydoxybenzotriazole
1-hydroxybenztria zole
1h-benzo[d][1,2,3]triazole-1-ol
1 -hydroxybenzotriazole
1-n-hydroxybenzotriazole
1hydroxy-benzotriazole
1-hyroxybenzotriazole
n-hydroxy-benzotriazol
1-hydroxybenztriazol
n-hydroxyl-benzotriazole
1-hydroxybezotriazole
1-hydroxybenzothazole
1-hydroxy benztriazole
1-hydroxy-benzo-1,2,3-triazole
1-hydroxy benzotriazol
SCHEMBL3295216
1h-benzotriazole, hydroxy-
F0001-2469
hobt,anhydrous
1-hydroxybenzotriazole (wet with 14% water)
Z56900935
cis-7-octadecenoicacidmethylester
benzotriazole n-oxide
1h-1,2,3-benzotriazol-1-ol (wet with 14% water)
Q161641
nsc-778225
nsc778225
EN300-17272
1-hydroxybenzotrizole
hydroxybenzotriazole (hobt)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" By changing the factors of laccase-mediated system pretreatment and the hydrogen peroxide bleaching process and examining the subsequent whiteness value and retained tensile strength of the samples, we find three LMS-HPBP processes that are more environment friendly than the conventional hydrogen peroxide bleaching process (CHPBP): (i) bleaching with lower dosage of hydrogen peroxide; (ii) bleaching at reduced temperature; (iii) bleaching for shortened duration."( Laccase-mediated system pretreatment to enhance the effect of hydrogen peroxide bleaching of cotton fabric.
Branford-White, C; Nie, H; Tian, L; Wang, W; Zhu, L, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzotriazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588456
AR proteinHomo sapiens (human)Potency3.46820.000221.22318,912.5098AID1259243; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency48.55770.000657.913322,387.1992AID1259377
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.89720.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency30.63790.001530.607315,848.9004AID1224841
aryl hydrocarbon receptorHomo sapiens (human)Potency76.95880.000723.06741,258.9301AID743085
serine-protein kinase ATM isoform aHomo sapiens (human)Potency1.25890.707925.111941.2351AID485349
DNA polymerase betaHomo sapiens (human)Potency8.91250.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency1.41250.039816.784239.8107AID1454
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID625725Inhibition of human recombinant indoleamine-2,3-dioxygenase expressed in Escherichia coli BL21 using L-tryptophan as substrate after 30 mins by microplate reader analysis2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (9.71)18.7374
1990's17 (16.50)18.2507
2000's31 (30.10)29.6817
2010's39 (37.86)24.3611
2020's6 (5.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.68 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index109.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other110 (99.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]